The glycome of normal and malignant plasma cells

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Moehler, Thomas M ^a,b   Seckinger, Anja ^a,c   Hose, Dirk ^a,c   Andrulis, Mindaugas ^a   Moreaux, Jèrôme ^d,e,f   Hielscher, Thomas ^b   Willhauck Fleckenstein, Martina ^b   Merling, Anette ^b   Bertsch, Uta ^a   Jauch, Anna ^g   Goldschmidt, Hartmut ^a,c   Klein, Bernard ^d,e,f   Schwartz Albiez, Reinhard ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Nationales Centrum fur Tumorerkrankungen   (Germany)

^d INSERM   (France)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

^f UNIV MONTPELLIER   (France)

^g UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MELPHALAN;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CHROMOSOME ABERRATION; CHROMOSOME DELETION 13; CHROMOSOME GAIN 1Q; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 4; CONTROLLED STUDY; DRUG MEGADOSE; EVENT FREE SURVIVAL; GENE EXPRESSION; GLYCOBIOLOGY; GLYCOME; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MYELOMA CELL; OVERALL SURVIVAL; PLASMA CELL;

CLUSTER ANALYSIS; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLYCOMICS; GLYCOSYLPHOSPHATIDYLINOSITOLS; HEPARITIN SULFATE; HUMANS; MANNOSYLTRANSFERASES; METABOLIC NETWORKS AND PATHWAYS; MULTIPLE MYELOMA; PLASMA CELLS; POLYSACCHARIDES;

EID: 84891286009     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083719     Document Type: Article

References (56)

1. Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351:1860- 1873.
2. Cremer FW, Bila J, Buck I, Kartal M, Hose D, et al. (2005) Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer 44:194-203. (Pubitemid 41306648)
3. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, et al. (2004) Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64:1546-1558. (Pubitemid 38235629)
4. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, et al. (2006) Longterm outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 135:158-164. (Pubitemid 44401612)
5. Harousseau JL, Moreau P (2009) Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 360:2645-2654.
6. Shaughnessy JD, Zhou Y, Haessler J, van RF, Anaissie E, et al. (2009) TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy. Br J Haematol 147:347-351.
7. Nair B, van Rhee F, Shaughnessy JD Jr, Anaissie E, Szymonifka J, et al. (2010) Superior results of Total Therapy 3 (2003-33) in gene expression profilingdefined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 115:4168-4173.
8. Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, et al. (2009) Induction of angiogenesis by normal and malignant plasma cells. Blood 114:128-143.
9. Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, et al. (2009) Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene 28:3866-3879.
10. Mahtouk K, Moreaux J, Hose D, Reme T, Meissner T, et al. (2010) Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays. BMC Cancer 10:198.
11. Lowe JB (2003) Glycan-dependent leukocyte adhesion and recruitment in inflammation. Curr Opin Cell Biol 15:531-538. (Pubitemid 37176961)
12. Pilobello KT, Mahal LK (2007) Deciphering the glycocode: the complexity and analytical challenge of glycomics. Curr Opin Chem Biol 11:300-305. (Pubitemid 46963071)
13. Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N (2004) Carbohydratemediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci 95:377-384. (Pubitemid 38832679)
14. Bret C, Hose D, Reme T, Sprynski AC, Mahtouk K, et al. (2009) Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells. Br J Haematol 145:350-368.
15. Bret C, Moreaux J, Schved JF, Hose D, Klein B (2011) SULFs in human neoplasia: implication as progression and prognosis factors. J Transl Med 9:72.
16. Mahtouk K, Hose D, Reme T, De Vos J, Jourdan M, et al. (2005) Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene 24:3512-3524.
17. Mahtouk K, Cremer FW, Reme T, Jourdan M, Baudard M, et al. (2006) Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene 25:7180-7191. (Pubitemid 44764187)
18. Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M (2002) Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 99:1405-1410. (Pubitemid 34547098)
19. Moreaux J, Sprynski AC, Dillon SR, Mahtouk K, Jourdan M, et al. (2009) APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop. Eur J Haematol 83:119-129.
20. Sprynski AC, Hose D, Caillot L, Reme T, Shaughnessy JD Jr, et al. (2009) The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 113:4614-4626.
21. Yang Y, MacLeod V, Miao HQ, Theus A, Zhan F, et al. (2007) Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 282:13326-13333. (Pubitemid 47100527)
22. Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, et al. (2007) Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 109:4914-4923. (Pubitemid 46827789)
23. Reijmers RM, Groen RW, Rozemuller H, Kuil A, de Haan-Kramer A, et al. (2010) Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma. Blood 115:601-604.
24. Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, et al. (2007) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109:2276- 2284. (Pubitemid 46425864)
25. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, et al. (2007) Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 109:3489-3495. (Pubitemid 46572539)
26. Hose D, Reme T, Hielscher T, Moreaux J, Messner T, et al. (2011) Proliferation is a central independent prognostic factor and target for personalized and riskadapted treatment in multiple myeloma. Haematologica 96:87-95.
27. Greipp PR, San MJ, Durie BG, Crowley J J, Barlogie B, et al. (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412-3420.
28. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, et al. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123. (Pubitemid 28435189)
29. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, et al. (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473. (Pubitemid 44264086)
30. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, et al. (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354:1021-1030. (Pubitemid 43357806)
31. Hose D, Reme T, Meissner T, Moreaux J, Seckinger A, et al. (2009) Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 113:4331-4340.
32. Gu ZJ, De VJ, Rebouissou C, Jourdan M, Zhang XG, et al. (2000) Agonist antigp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia 14:188-197. (Pubitemid 30068391)
33. Rebouissou C, Wijdenes J, Autissier P, Tarte K, Costes V, et al. (1998) A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. Blood 91:4727-4737. (Pubitemid 28270323)
34. Zhang XG, Olive D, Devos J, Rebouissou C, Ghiotto-Ragueneau M, et al. (1998) Malignant plasma cell lines express a functional CD28 molecule. Leukemia 12:610-618. (Pubitemid 28197587)
35. Meissner T, Seckinger A, Reme T, Hielscher T, Moehler TM, et al. (2011) Gene expression profiling in multiple myeloma - reporting of entities, risk, and targets in clinical routine. Clin Cancer Res 17:7240-7247.
36. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408. (Pubitemid 34164012)
37. Willhauck-Fleckenstein M, Moehler TM, Merling A, Pusunc S, Goldschmidt H (2010) Transcriptional regulation of the vascular endothelial glycome by angiogenic and inflammatory signalling. Angiogenesis 13:25-42.
38. Warren P, Taylor D, Martini P, Jackson J, Bienkowska JR (2007) PANP-a new method of gene detection on oligonucleotide expression arrays. BIBE 2007 Proceedings of the 7th IEEE International conference on Bioinformatics and Bioengineering 108-115.
39. Erdmann M, Wipfler D, Merling A, Cao Y, Claus C, et al. (2006) Differential surface expression and possible function of 9-O- and 7-O-acetylated GD3 (CD60 b and c) during activation and apoptosis of human tonsillar B and T lymphocytes. Glycoconj J 23:627-638. (Pubitemid 44934187)
40. Neben K, Lokhorst HM, Jauch A, et al. (2012) Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 119:940-948.
41. Wuilleme S, Robillard N, Lode L, Magrangeas F, Bersi H, et al. (2005) Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia 19:275-278. (Pubitemid 40220593)
42. Andrulis M, Dietrich S, Longerich T, Koschny R, Burian M, et al (2012) Loss of endothelial thrombomodulin predicts response to steroid therapy and survival in acute intestinal graft-versus-host disease. Haematologica 97:1674-1677.
43. Wu Z, Irizarry RA, Gentleman RC, Martinez-Murillo F, SF (2004) A modelbased background adjustment for oligonucleotide expression arrays. Journal of the American Statistical Association 99:909-917. (Pubitemid 39665934)
44. Taylor J, Tibshirani R, Efron B (2005) The 'miss rate' for the analysis of gene expression data. Biostatistics 6:111-117. (Pubitemid 41240373)
45. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:Article3.
46. Shi L, Campbell G, Jones WD, Campagne F, Wen Z, et al. (2010) The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 28:827-838.
47. Goeman J J, van de Geer SA, de Kort F, van Houwelingen HC (2004) A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 20:3-99.
48. Nikesch J-H, Buerger H, Simon R, Brandt B (2006) Decay-accelerating factor(CD55): A versatile acting molecule in human malignancies. Biochim Biophys Acta 1766:42-52. (Pubitemid 44175633)
49. Jurianz K, Ziegler S, Garcia-Schü ler H, Kraus S, Bohana-Kashtan O, et al. (1999) Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 36:929-939.
50. Paulick MG, Bertozzi CR (2008) The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins. Biochemistry 47:6991- 7000. (Pubitemid 351956348)
51. Filmus J, Capurro M, Rast J (2008) Glypicans. Genome Biol 9:224.
52. Irie A, Takami M, Kubo H, Sekino-Suzuki N, Kasahara K, et al. (2007) Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone 41:165-174. (Pubitemid 47001824)
53. Reijmers R, Spaargaren M, Pals ST (2013) Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma. FEBS J 280:2180-2193.
54. Engelmann S, Ebeling O, Schwartz-Albiez R (1995) Modulated glycosylation of proteoglycans during differentiation of human B lymphocytes. Biochim Biophys Acta 1267:6-14.
55. Kirschfink M, Blase L, Engelmann S, Schwartz-Albiez R (1997) Secreted chondroitin sulfate proteoglycan of human B cell lines binds to the complement protein C1q and inhibits complex formation of C1. J Immunol 158:1324-1331. (Pubitemid 127469958)
56. Engelmann S, Schwartz-Albiez R (1997) Differential release of proteoglycans during human B lymphocyte maturation. Carbohydr Res 302:85-95. (Pubitemid 27343480)